Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2008, Pages 210-216

  Fathi, Amir T ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

advanced stage; combination chemotherapy; non small cell lung cancer; systemic therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; TENIPOSIDE;

ADVANCED CANCER; ANEMIA; ARTERY EMBOLISM; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEMOPTYSIS; HUMAN; HYPERTENSION; LARGE CELL CARCINOMA; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROTEINURIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56349162168     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2008.09.002     Document Type: Article

References (40)

1. Abeloff M.D., Armitage J.O., Niederhuber J.E., et al. Clinical Oncology. (ed 3) (2004), Elsevier Churchill Livingstone, Philadelphia, PA 1701-1722
2. Bunn P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4 (1998) 1087-1100
3. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 16 (1998) 2459-2465
4. Sandler A., Nemunaitis J., Deham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18 (2000) 122-130
5. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 18 (2000) 623-631
6. Giaccone G., Splinter T.A.W., Debruyne C., et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 2133-2141
7. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a southwest oncology group trial. J Clin Oncol 19 (2001) 3210-3218
8. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
9. Favaretto A., Ceresoli G.L., Paccagnella A., et al. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Ann Oncol 11 (2000) 1421-1426
10. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26 (2008) 3543-3551
11. Edelman M.J., Gandara D.R., Lau D.H.M., et al. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92 (2001) 146-152
12. Chiappori A., Simon G., Williams C., et al. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68 (2005) 382-390
13. Binder D., Schweisfurth H., Grah C., et al. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicenter randomized phase II trial. Cancer Chemother Pharmacol 60 (2007) 143-150
14. Ramalingam S., and Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. The Oncologist 13 suppl 1 (2008) 1-13
15. Fidias P., Dakhil S.R., Lyss A.P., et al. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer. J Clin Oncol 24 18 suppl (2006) 7032
16. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52 (2006) 155-163
17. Bhatia S., Hanna N., Ansari R., et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIB and IV non-small cell lung cancer. Lung Cancer 38 (2002) 73-77
18. Giaccone G., Smith E.F., van Meerbeeck J.P., et al. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 11 (2000) 109-112
19. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non small cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
20. Georgoulias V., Kouroussis C., Androulakis N., et al. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17 (1999) 914-920
21. Georgoulias V., Samonis G., Papadakis E., et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34 (2001) S47-S51
22. Ziotopoulos P., Androulakis N., Mylonaki E., et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicenter phase II study. Lung Cancer 50 (2005) 115-122
23. Yamamoto N., Fukuoka M., Negoro S.I., et al. Randomized phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small cell lung cancer: a west Japan thoracic oncology group study. Br J Cancer 90 (2004) 87-92
24. Han J.Y., Lee D.H., Song J.E., et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced non-small cell lung cancer. Cancer 113 (2008) 388-395
25. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
26. Manegold C. Bevacizumab for the treatment of advanced non-small cell lung cancer. Expert Rev Anticancer Ther 8 (2008) 689-699
27. Jain R.K. Normalizing tumor vasculature with anti-agiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
28. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
29. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 355 (2006) 2542-2550
30. Manegold C., Von Pawel J., Zatloukal P., et al. Randomized, double-blind, multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 20 suppl (2007) 25 (abstract LBA 7514)
31. Gridelli C., Perrone F., Gallo C., et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer: a two-stage phase II study. Eur J Cancer 33 (1997) 392-397
32. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. The Oncologist 6 suppl 1 (2001) 4-7
33. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34 (2001) S65-S69
34. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
35. Fossella F., DeVore R., Kerr R., et al. Randomized phase-III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
36. Shephard F., Dancey J., Ramlou R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 8 (2000) 2095-2103
37. Stinchcombe T.E., and Socinski M.A. Considerations for second-line therapy of non-small cell lung cancer. The Oncologist 13 suppl 1 (2008) 28-36
38. Rusthoven J.J., Eisenhauer E., Butts C., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 17 (1999) 1194-1199
39. Smit E.F., Mattson K., von Pawel J., et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14 (2003) 455-460
40. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597